Stem, Inc. (STEM)
$
18.67
+1.43 (7.66%)
Key metrics
Financial statements
Free cash flow per share
-2.2369
Market cap
156.6 Million
Price to sales ratio
0.9497
Debt to equity
-1.3681
Current ratio
0.8256
Income quality
-0.1271
Average inventory
4.9 Million
ROE
-0.3246
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Stem, Inc. operates as a digitally connected and intelligent energy storage network provider in the United States and internationally. The EBITDA is -$790,401,000.00 a key indicator of the company's operational profitability. The cost of revenue for the company is $155,642,000.00 showcasing its production and operational expenses. Despite its advanced solutions, the company reported a net loss of -$854,014,000.00 indicating challenges in its operations. Furthermore, the earnings per share (EPS) is reported at -$105.80 indicating the company's profitability on a per-share basis. The income before tax ratio is -$5.90 reflecting the pre-tax margin. Stem, Inc. provides energy storage systems sourced from original equipment manufacturers (OEMs) and offers its innovative Athena artificial intelligence platform, which delivers battery hardware and software-enabled services for optimal operation of energy storage systems. Additional services include system design and engineering, supply chain management, energy storage value stream optimization, and program enrollment and incentive management services. The company caters to commercial and industrial enterprises, independent power producers, renewable project developers, as well as utilities and grid operators, and it was incorporated in 2009 with headquarters in San Francisco, California. The stock is affordable at $18.10 suitable for budget-conscious investors. It also boasts a high average trading volume of 349,082.00 indicating strong liquidity. With a market capitalization of $156,645,183.00 the company is classified as a small-cap player. Stem, Inc. is a key player in the Software - Infrastructure industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Technology sector, driving innovation and growth. Overall, Stem, Inc. combines cutting-edge technology with proactive management to enhance energy storage solutions while navigating the complexities of the market effectively.
Is Stem, Inc. (STEM) a good investment?
Investing in Stem, Inc. (STEM) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Stem, Inc. (STEM)'s stock forecast?
Analysts predict Stem, Inc. stock to fluctuate between $5.82 (low) and $33.60 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Stem, Inc.'s market capitalization?
As of 2025-12-04, Stem, Inc.'s market cap is $156,645,183, based on 8,390,208 outstanding shares.
How does Stem, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Stem, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Stem, Inc. (STEM) stock?
To buy Stem, Inc. (STEM) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for STEM. Place an order (Market, Limit, etc.).
What is the best time to invest in Stem, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Stem, Inc. stock ever split?
Stem, Inc.'s last stock split was 1:20 on 2025-06-23.
How did Stem, Inc. perform in the last earnings report?
Revenue: $144,584,000 | EPS: -$105.80 | Growth: 486.16%.
Where can I find Stem, Inc.'s investor relations reports?
Visit https://www.stem.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Stem, Inc.?
You can explore historical data from here
What is the all-time high and low for Stem, Inc. stock?
All-time high: $32.23 (2025-10-15) | All-time low: $0.29 (2025-04-16).
What are the key trends affecting Stem, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
HOUSTON--(BUSINESS WIRE)--Stem, Inc. (NYSE: STEM), a global leader reimagining technology to support the energy transition, today announced that its Board of Directors has increased the size of the Board from seven to eight directors, and appointed Arun Narayanan, Stem's Chief Executive Officer, to serve as a Class I Director, effective Dec. 1, 2025. The appointment reflects the Board's confidence in Narayanan's leadership and strategic vision as Stem continues to execute its transformation to.
defenseworld.net
Stem, Inc. (NYSE: STEM - Get Free Report) has been assigned a consensus recommendation of "Reduce" from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have issued a hold recommendation on the company. The average 1-year price target
seekingalpha.com
Stem, Inc. ( STEM ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Erin Reed Arun Narayanan - Chief Executive Officer Brian Musfeldt - Chief Financial Officer Conference Call Participants Justin Clare - ROTH Capital Partners, LLC, Research Division Jonathan Windham - UBS Investment Bank, Research Division Thomas Roche - Barclays Bank PLC, Research Division Presentation Operator Ladies and gentlemen, greetings, and welcome to the Stem, Inc. Third Quarter 2025 Results Conference Call. [Operator Instructions].
zacks.com
Stem, Inc. (STEM) came out with a quarterly loss of $2.84 per share versus the Zacks Consensus Estimate of a loss of $1.85. This compares to a loss of $4.2 per share a year ago.
247wallst.com
Stem beat on revenue but missed on earnings, causing the stock to sell off in after hours.
globenewswire.com
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company, announces that Chris Ehrlich, Chief Executive Officer will participate in a stem cell therapy panel titled, “A Space That is Ready to Have its Day,” at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 23, 2025 at the Hard Rock Hotel in New York City.
businesswire.com
BERLIN--(BUSINESS WIRE)--Stem, Inc. (NYSE: STEM), a global leader reimagining technology to support the energy transition, today announced the expansion of its Berlin operations with a move to centralized and collaborative facilities. The new office underscores Stem's commitment to advancing utility-scale solar, storage and hybrid solar-plus-storage projects across the EMEA region. The enhanced 400-square-meter space nearly doubles workspace capacity, bringing Stem's engineering, sales, and cus.
businesswire.com
HOUSTON--(BUSINESS WIRE)--Stem (NYSE: STEM), a global leader in AI-enabled clean energy software and services, will hold a conference call on Wed., Oct. 29, 2025, to discuss its results for the quarter ended Sept. 30, 2025. The conference call is scheduled to begin at 5:00 p.m. Eastern Time. A press release regarding the results will be issued at approximately 4:05 p.m. Eastern Time. The conference call may be accessed via a live webcast on a listen-only basis at https://investors.stem.com/even.
globenewswire.com
HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the publication of an opinion editorial authored by company leadership that presents the scientific case for fibroblast cells' therapeutic advantages compared to stem cell therapies.
businesswire.com
HOUSTON--(BUSINESS WIRE)--Stem, Inc. (NYSE: STEM): Sept. 9, 2025 Dear Stem Shareholders, It has been 12 months since we announced our strategic realignment, and I want to take the opportunity to reflect on the strides we have made in transforming our business. This year has marked a journey in strategic change and realignment, and we are well on our way to success. Our progress is reflected in our latest quarterly earnings results, including driving our software and services offerings and posit.
See all news
